Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0099)
| Name |
Lycopene
|
||||
|---|---|---|---|---|---|
| Synonyms |
LYCOPENE; 502-65-8; all-trans-Lycopene; Psi,psi-carotene; trans-Lycopene; Lycopene 7; lycored; Redivivo; Mexoryl SAQ; Tomat-O-Red; (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; (all-trans)-lycopene; Lycopene, all-trans-; TOMATO LYCOPENE; Aec lycopene; (all-e)-lycopene; CI 75125; Solanorubin; Ateronon; CCRIS 7925; NSC 407322; UNII-SB0N2N0WV6; Blakeslea trispora; C.I. 75125; EINECS 207-949-1; SB0N2N0WV6; INS-160D(III); INS NO.160D(III); Lycopene from blakeslea trispora; DTXSID2046593; FEMA NO. 4110; CHEBI:15948; E-160D(III); NSC-407322; LYC-O-MATO; DTXCID0026593; NSC407322; (all-E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; NCGC00166291-01; .psi.,.psi.-Carotene; LYCOPENE (MART.); LYCOPENE [MART.]; Lycopene (VAN); cis-Lycopene; LYCOPENE PREPARATION (USP-RS); LYCOPENE PREPARATION [USP-RS]; MFCD00017350; All trans Lycopene; psi, psi-Carotene; LYC; LyocpenePowder; psi-psi-carotene; y,y-Carotene; Lyco Vit; Lycopene preparation; Lycopene all-trans-; LYCOPENE [INCI]; LYCOPENE [MI]; LYCOPENE [VANDF]; LYCOPENE [WHO-DD]; BSPBio_003389; Lycopene, analytical standard; E160d; TOMATO LYCOPENE [FHFI]; CHEMBL501174; Lycopene, >=90%, from tomato; CI 75125 [INCI]; HY-N0287; Tox21_112395; LMPR01070257; s3943; AKOS015961276; CS-6378; DB11231; FD10111; NCGC00166291-02; NCGC00166291-03; NCGC00166291-04; 2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; AC-13571; AC-33932; CAS-502-65-8; LS-15428; Lycopene, >=98% (HPLC), from tomato; L0257; LYCOPENE FROM BLAKESLEA TRISPORA [FCC]; C05432; Q208130; Q-100561; Lycopene, United States Pharmacopeia (USP) Reference Standard; Lycopene, Pharmaceutical Secondary Standard; Certified Reference Material; (ALL-E)-LYCOPENE (CONSTITUENT OF LYCOPENE AND TOMATO EXTRACT CONTAINING LYCOPENE); (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-octamethyl-, (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-Octamethyl-, (all-E)-
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C40H56
|
||||
| IUPAC Name |
(6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene
|
||||
| Canonical SMILES |
CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)C)C
|
||||
| InChI |
InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+
|
||||
| InChIKey |
OAIJSZIZWZSQBC-GYZMGTAESA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Injury of intra-abdominal organs | ICD-11: NB91 | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | mSCs (Mouse splenocytes) | ||||
| In Vivo Model |
Three-week-old specific pathogen-free ICR (Institute of Cancer Research) male mice (weights of 18-22 g) were provided by Liaoning Changsheng Biotech Co. Ltd. The mice were housed under conditions at 22 ± 2 with 35-65% humidity and a light/dark cycle of 12 h/12 h in the cage. The animals were quarantined for a week before formal experiments, then randomly divided into seven groups: vehicle control group (Vcon), control group (Con), 5 mg/kg BW/d Lyc group (Lyc), 500 and 1000 mg/kg BW/d DEHP group (D5 and D10, respectively), DEHP + Lyc group (DL5 and DL10, respectively) (n = 20). The animals were exposed to DEHP via oral gavage, which lasted for 28 d, and then sacrificed after being anesthetized.
Click to Show/Hide
|
||||
| Response regulation | DEHP disrupted the GSH metabolism via the xc/ GPX4 antioxidant system and, subsequently, caused the ferroptotic cell death, but Lycopene (Lyc) could effectively mitigate DEHP-induced damage to the antioxidant system. These findings indicated that Lyc may be an effective strategy for the prevention of DEHP-induced splenic toxicity via the regulation of ferroptosis. | ||||